Inhibrx Biosciences, Inc.
INBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $223 | $1,791 | $988 | $1,660 |
| - Cash | $153 | $278 | $274 | $131 |
| + Debt | $8 | $210 | $207 | $70 |
| Enterprise Value | $78 | $1,723 | $921 | $1,599 |
| Revenue | $0 | $2 | $2 | $7 |
| % Growth | -88.9% | -17.9% | -69.2% | – |
| Gross Profit | -$2 | $1 | -$108 | $4 |
| % Margin | -1,042.5% | 33.8% | -4,926.7% | 62.3% |
| EBITDA | $1,703 | -$207 | -$126 | -$75 |
| % Margin | 851,675% | -11,482.9% | -5,739.8% | -1,057.8% |
| Net Income | $1,688 | -$241 | -$145 | -$82 |
| % Margin | 843,786% | -13,408.9% | -6,625.3% | -1,147.6% |
| EPS Diluted | 116.58 | -5.12 | -3.62 | -2.15 |
| % Growth | 2,377% | -41.4% | -68.4% | – |
| Operating Cash Flow | -$194 | -$193 | -$115 | -$80 |
| Capital Expenditures | -$3 | -$5 | -$1 | -$1 |
| Free Cash Flow | -$197 | -$198 | -$116 | -$81 |